The list includes "high throughput DNA sequence analyzer," "DNA genetic analyzer," and "mass spectrometer for clinical multiplex test systems."
The firm's ROS1 gene fusion kit was approved as a companion diagnostic for Pfizer's Xalkori.
The FDA granted Abbott Emergency Use Authorization for the assay in serum, plasma, and urine in November.
New data suggest that measuring AR-V7 expression only in the nuclei of circulating tumor cells might better predict therapeutic benefit in prostate cancer patients.
The RealStar Zika Virus RT-PCR Kit 1.0 has been listed by the World Health Organization as eligible for procurement agencies and member states.
The company's subsidiary Viracor-IBT can now run the real time, reverse transcriptase-PCR assay for patients meeting clinical or epidemiological criteria for Zika.
The results support the tests potential to more specifically predict high-risk prostate cancers, and lower the number of unnecessary prostate biopsies.
Japanese researchers uncovered recurrent DUX4 fusions in adolescent or young adult cases of B-cell acute lymphoblastic leukemia, along with other new ALL fusions.
With the help of TCGA sequence data, researchers uncovered expression of a long, non-coding RNA called SAMMSON that appears to be specific to melanoma.
The South Korean company said the kit not only detects Zika, but is also set up to find multiple mosquito-borne diseases such as Dengue and Chikunguya.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.